Loading organizations...
§ Private Profile · Seattle, WA, USA
Silverback Therapeutics is a technology company.
Silverback Therapeutics develops innovative tissue-targeted therapeutics using its proprietary ImmunoTAC technology platform. This systemically delivered platform precisely activates immune cell subsets directly within disease sites. The company focuses on precision medicines for cancer and chronic viral infections, localizing drug activity to enhance therapeutic efficacy.
Founded in 2016 by Badreddin Edris and Peter Thompson, Silverback Therapeutics originated from an insight into safely directing immunomodulators to specific disease tissues. Their vision addressed systemic toxicity in traditional immunotherapy by enabling localized immune activation. Dr. Edris's drug discovery experience shaped the company's foundational scientific approach.
Silverback Therapeutics strives to provide novel treatment options for patients battling advanced cancers and chronic viral diseases. The company’s long-term vision centers on transforming immunology and oncology by developing highly selective and potent therapies. This approach seeks to improve patient outcomes with reduced side effects, establishing a new paradigm in targeted immunotherapy.
Silverback Therapeutics has raised $201.5M across 3 funding rounds.
Silverback Therapeutics has raised $201.5M in total across 3 funding rounds.
Silverback Therapeutics has raised $201.5M across 3 funding rounds. Most recently, it raised $85.0M Series C in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2020 | $85M Series C | Scott Platshon | Andreessen Horowitz, Canaan Partners, Deerfield Management, Nextech Invest, U.S. Venture Partners, Boxer Capital, Fidelity Management & Research Company, Hunt Technology Ventures, Nantahala Capital Management, Nextech Invest, OrbiMed, Pontifax, RA Capital Management | Announced |
| Mar 1, 2020 | $79M Series B | U.S. Venture Partners | Andreessen Horowitz, Canaan Partners, Deerfield Management, Nextech Invest, Alexandria Venture Investments, Bristol Myers Squibb, Colt Ventures, Hunt Investment Group, Thilo Schroeder, NS Investment, OrbiMed, Pontifax | Announced |
| Sep 19, 2018 | $37.5M Series A Plus | — | Alexandria Venture Investments, Celgene, Peter Thompson | Announced |
Silverback Therapeutics has raised $201.5M in total across 3 funding rounds.
Silverback Therapeutics's investors include Scott Platshon, Andreessen Horowitz, Canaan Partners, Deerfield Management, Nextech Invest, U.S. Venture Partners, Boxer Capital, Fidelity Management & Research Company, Hunt Technology Ventures, Nantahala Capital Management, OrbiMed, Pontifax.
Silverback Therapeutics, Inc. (NASDAQ: SBTX) was a clinical-stage biopharmaceutical company that developed tissue-targeted therapeutics using its proprietary ImmunoTAC™ platform to treat cancer, autoimmune diseases, chronic viral infections, fibrosis, and other serious conditions.[1][2][3][4] The company aimed to create potent, locally-acting therapies that modulated immune pathways at disease sites, minimizing systemic toxicities, and served patients with oncology and immunology needs by addressing unmet challenges in precise immune modulation.[1][2][3] Its growth included an IPO but faced setbacks with program discontinuations in 2022, culminating in a reverse merger with ARS Pharmaceuticals in November 2022, after which Silverback ceased independent operations.[2]
Founded in 2016 and headquartered in Seattle, Silverback Therapeutics emerged from the biotech hub in the Pacific Northwest to pioneer ImmunoTAC™, pairing linker-payloads with monoclonal antibodies for site-specific immune modulation.[2][3] The idea stemmed from a need for therapies that acted locally to improve outcomes in cancer and autoimmune diseases without broad toxicity, backed by investors like those in its funding rounds.[1][2] Early traction built through clinical development, but pivotal moments included a March 2022 restructuring with lead program halts and a July 2022 merger announcement with ARS Pharmaceuticals, leading to the end of standalone operations by November 2022.[2]
Silverback rode the wave of precision immunology and tissue-targeted therapies, a key trend in biotech amid rising demand for localized treatments over systemic ones to enhance efficacy and safety in cancer and autoimmune markets.[1][2][3] Timing aligned with advances in antibody-linker tech during the late 2010s biotech boom, bolstered by Seattle's ecosystem for talent and research.[2] Market forces like investor interest in immuno-oncology favored it initially, influencing the field by validating ImmunoTAC™-like platforms now pursued by others post-merger.[2][4]
Silverback's legacy as an innovator in targeted immunotherapies ended with its 2022 merger into ARS Pharmaceuticals, shifting focus to allergy treatments like neffy® rather than its original pipeline.[2] No independent future exists, but its ImmunoTAC™ concepts could inspire ongoing biotech trends in precision medicine. Influence may evolve through acquired IP or alumni driving similar ventures in immunology. This biotech's arc—from promising platform to strategic pivot—highlights the high-stakes dynamics of clinical-stage development.[2]